CAPER, a novel regulator of human breast cancer progression

Cell Cycle

Volumn 13, Issue 8, 2014, Pages 1256-1264

  Mercier, Isabelle ^a,b   Gonzales, Donna M ^a   Quann, Kevin ^a   Pestell, Timothy G ^a   Molchansky, Alexander ^a   Sotgia, Federica ^a,c   Hulit, James ^c   Gandara, Ricardo ^c   Wang, Chenguang ^a   Pestell, Richard G ^d   Lisanti, Michael P ^a,c   Jasmin, Jean François ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Breast cancer; CAPER; Estrogen receptor; Proliferation; Tumor growth

Indexed keywords

COACTIVATOR OF ACTIVATING PROTEIN 1; CYCLIN D1; ESTROGEN RECEPTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; LENTIVIRUS VECTOR; MINICHROMOSOME MAINTENANCE PROTEIN 7; PROTEIN C JUN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CYCLINE; HCC1 AUTOANTIGEN; NUCLEAR PROTEIN; RNA BINDING PROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CARCINOGENICITY; CELL CYCLE REGULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TUMOR VOLUME; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CYCLE CHECKPOINT; DISEASE COURSE; GENETICS; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-JUN; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84899061594     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28156     Document Type: Article

References (54)

1. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15:17-35; PMID:8405201
2. Gustafsson JA. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998; 2:508-11; PMID:9736924; http://dx.doi.org/10.1016/S1367-5931(98)80127-0
3. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87:905-31; PMID:17615392; http://dx.doi.org/10.1152/physrev.00026.2006
4. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344:276-85; PMID:11172156; http://dx.doi.org/10.1056/NEJM200101253440407
5. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996; 17:47-67; PMID:8724215; http://dx.doi.org/10.1146/ annurev.pu.17.050196.000403
6. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 1986; 24:77-83; PMID:2422449; http://dx.doi.org/10.1016/0022-4731(86) 90035-X
7. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231:1150-4; PMID:3753802; http://dx.doi.org/10.1126/science.3753802
8. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93:5925-30; PMID:8650195; http://dx.doi.org/10.1073/pnas.93.12.5925
9. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108:465-74; PMID:11909518; http://dx.doi.org/10.1016/S0092-8674(02)00641-4
10. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276:36869-72; PMID:11459850; http://dx.doi.org/10.1074/jbc.R100029200
11. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999; 155:1811-5; PMID:10595909; http://dx.doi.org/10.1016/S0002-9440(10)65498-3
12. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999; 188:237-44; PMID:10419589; http://dx.doi.org/10.1002/(SICI)1096-9896(199907)188:3<237:: AIDPATH343>3.0.CO;2-8
13. Vogel VG, Lo S. Preventing hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003; 95:91-3; PMID:12529335; http://dx.doi.org/10. 1093/jnci/95.2.91
14. nd, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res 1990; 50:6208-17; PMID:2400987
15. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 2001; 61:1721-33; PMID:11693462; http://dx.doi.org/10.2165/00003495-200161120-00004
16. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53:25-71; PMID:11171938
17. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11:643-58; PMID:15613444; http://dx.doi.org/10.1677/erc.1.00776
18. Tremblay GB, Giguère V. Coregulators of estrogen receptor action. Crit Rev Eukaryot Gene Expr 2002; 12:1-22; PMID:12433063; http://dx.doi.org/10. 1615/CritRevEukaryotGeneExpr.v12.i1.10
19. Jung DJ, Na SY, Na DS, Lee JW. Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. J Biol Chem 2002; 277:1229-34; PMID:11704680; http://dx.doi.org/10.1074/jbc. M110417200
20. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, et al. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 2009; 174:1172-90; PMID:19342371; http://dx.doi.org/10. 2353/ajpath.2009.080882
21. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993; 92:2419-26; PMID:8227358; http://dx.doi.org/10. 1172/JCI116848
22. Dowhan DH, Hong EP, Auboeuf D, Dennis AP, Wilson MM, Berget SM, O'Malley BW. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol Cell 2005; 17:429-39; PMID:15694343; http://dx.doi.org/10.1016/j.molcel.2004.12.025
23. Dutta J, Fan G, Gélinas C. CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel. J Virol 2008; 82:10792-802; PMID:18753212; http://dx.doi.org/10.1128/JVI.00903-08
24. Huang G, Zhou Z, Wang H, Kleinerman ES. CAPER-alpha alternative splicing regulates the expression of vascular endothelial growth factor(165) in ewing sarcoma cells. Cancer 2011
25. Sillars-Hardebol AH, Carvalho B, Beliën JA, de Wit M, Delis-van Diemen PM, Tijssen M, van de Wiel MA, Pontén F, Meijer GA, Fijneman RJ. CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression. Cell Oncol (Dordr) 2012; 35:293-300; PMID:22711543; http://dx.doi.org/10.1007/s13402- 012-0088-2
26. Sillars-Hardebol AH, Carvalho B, Tijssen M, Beliën JA, de Wit M, Delis-van Diemen PM, Pontén F, van de Wiel MA, Fijneman RJ, Meijer GA. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut 2012; 61:1568-75; PMID:22207630; http://dx.doi.org/10.1136/ gutjnl-2011-301153
27. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997; 272:10882-94; PMID:9099745; http://dx.doi.org/10.1074/jbc.272.16.10882
28. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7:812-21; PMID:8491378; http://dx.doi.org/10.1101/gad.7.5.812
29. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A 1994; 91:8022-6; PMID:8058751; http://dx.doi.org/10.1073/pnas.91.17.8022
30. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994; 9:707-18; PMID:8108113
31. Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR, Afshari CA. Regulation of DNA replication fork genes by 17beta-estradiol. Mol Endocrinol 2002; 16:1215-29; PMID:12040010
32. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51:3867-73; PMID:1855205
33. Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, Nicholson RI, Sutherland RL. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 1996; 2:923-8; PMID:9816251
34. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999; 5:2069-76; PMID:10473088
35. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326:515-7; PMID:2882423; http://dx.doi.org/10.1038/326515a0
36. Zuber M, Tan EM, Ryoji M. Involvement of proliferating cell nuclear antigen (cyclin) in DNA replication in living cells. Mol Cell Biol 1989; 9:57-66; PMID:2564636
37. Lottering ML, de Kock M, Viljoen TC, Grobler CJ, Seegers JC. 17beta-Estradiol metabolites affect some regulators of the MCF-7 cell cycle. Cancer Lett 1996; 110:181-6; PMID:9018099; http://dx.doi.org/10.1016/S0304- 3835(96)04489-8
38. Tahan SR, Neuberg DS, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71:3552-9; PMID:8098267; http://dx.doi.org/10.1002/1097-0142(19930601)71:11<3552::AID- CNCR2820711115>3.0.CO;2-N
39. Tanaka T, Knapp D, Nasmyth K. Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs. Cell 1997; 90:649-60; PMID:9288745; http://dx.doi.org/10.1016/S0092-8674(00)80526-7
40. Gladden AB, Diehl JA. The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB.MCM7 binding. J Biol Chem 2003; 278:9754-60; PMID:12519773; http://dx.doi.org/10.1074/jbc.M212088200
41. Heesom KJ, Gampel A, Mellor H, Denton RM. Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol 2001; 11:1374-9; PMID:11553333; http://dx.doi.org/10.1016/ S0960-9822(01)00422-5
42. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 2004; 64:8639-42; PMID:15574771; http://dx.doi.org/10.1158/0008-5472.CAN-04-2677
43. Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Cancer Res 2006; 66:9461-6; PMID:17018601; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-1895
44. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J, Ramon y Cajal S. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13:81-9; PMID:17200342; http://dx.doi.org/10.1158/1078-0432. CCR-06-1560
45. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20:2438-52; PMID:11402339; http://dx.doi.org/10.1038/sj.onc.1204385
46. Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007; 7:317-24; PMID:17979626; http://dx.doi.org/10. 2174/156800907780809723
47. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999; 18:6063-70; PMID:10557095; http://dx.doi.org/10.1038/sj.onc.1202989
48. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002; 21:7680-9; PMID:12400010; http://dx.doi.org/10.1038/sj.onc.1205883
49. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008; 27:366-77; PMID:17637753; http://dx.doi.org/10.1038/sj. onc.1210643
50. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76:1025-37; PMID:8137421; http://dx.doi.org/10.1016/0092-8674(94)90380-8
51. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993; 7:2135-48; PMID:8224842; http://dx.doi.org/10.1101/gad.7.11.2135
52. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996; 383:453-7; PMID:8837781; http://dx.doi.org/10.1038/383453a0
53. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000; 408:211-6; PMID:11089976; http://dx.doi.org/10.1038/35041591
54. Wang H, Sun X, Luo Y, Lin Z, Wu J. Adapter protein NRBP associates with Jab1 and negatively regulates AP-1 activity. FEBS Lett 2006; 580:6015-21; PMID:17052710; http://dx.doi.org/10.1016/j.febslet.2006.10.002